Phenomix Sciences has raised USD 5.5 million in a Series A funding round, with participation from existing investor Health2047 and new investors DexCom Inc. and Labcorp. Additionally, the company received a USD 2.3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).
The raised funds are expected to accelerate the commercialization of the MyPhenome test in the sector of obesity specialists and the broader industry. The test is claimed to identify obesity phenotypes and provide physicians with tools to create effective treatment plans, including lifestyle and diet interventions, as well as medication and procedure recommendations.
Phenomix Sciences is a biotechnology company focused on precision medicine for obesity treatment. It leverages genetic testing and data analytics to categorize obesity into phenotypes, which enables personalized treatment plans to optimize outcomes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.